Pourvaziri Ali, Mroueh Nayla, Cochran Rory L, Srinivas Rao Shravya, Kambadakone Avinash
Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114.
Radiol Imaging Cancer. 2025 May;7(3):e240142. doi: 10.1148/rycan.240142.
In the era of precision medicine, imaging plays a critical role in evaluating treatment response to various oncologic therapies. For decades, conventional morphologic assessments using cross-sectional imaging have been the standard for monitoring the effectiveness of systemic and locoregional therapies in patients with cancer. However, the development of new functional imaging tools has widened the scope of imaging from mere response assessment to patient selection and outcome prediction. Dual-energy CT (DECT), known for its superior material differentiation capabilities, shows promise in enhancing treatment response evaluation. DECT-based iodine quantification methods are increasingly being investigated as surrogates for assessing tumor vascularity and physiology, which is particularly important in patients undergoing emerging targeted therapies. The purpose of this review article is to discuss the current and emerging role of DECT in assessing treatment response in patients with malignant abdominal tumors. CT-Dual Energy, Transcatheter Tumor Therapy, Tumor Response, Iodine Uptake, Therapeutic Response © RSNA, 2025.
在精准医学时代，影像学在评估各种肿瘤治疗的反应中起着关键作用。几十年来，使用横断面成像的传统形态学评估一直是监测癌症患者全身和局部区域治疗效果的标准。然而，新的功能成像工具的发展将成像范围从单纯的反应评估扩展到患者选择和预后预测。双能CT（DECT）以其卓越的物质区分能力而闻名，在增强治疗反应评估方面显示出前景。基于DECT的碘定量方法越来越多地被研究作为评估肿瘤血管生成和生理学的替代指标，这在接受新兴靶向治疗的患者中尤为重要。这篇综述文章的目的是讨论DECT在评估恶性腹部肿瘤患者治疗反应中的当前和新兴作用。CT双能、经导管肿瘤治疗、肿瘤反应、碘摄取、治疗反应 ©RSNA，2025年。
